J Stritzelberger1, L Distel1, R Buslei1,2, R Fietkau1, F Putz3. 1. Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitaetsstraße 27, 91054, Erlangen, Germany. 2. Department of Neuropathology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany. 3. Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitaetsstraße 27, 91054, Erlangen, Germany. florian.putz@uk-erlangen.de.
Abstract
PURPOSE: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. While the alkylating agent temozolomide (TMZ) has prolonged overall survival, resistance evolution represents an important clinical problem. Therefore, we studied the effectiveness of radiotherapy and CCNU in an in vitro model of acquired TMZ resistance. METHODS: We studied the MGMT-methylated GBM cell line U251 and its in vitro derived TMZ-resistant subline, U251/TMZ-R. Cytotoxicity of TMZ, CCNU, and radiation was tested. Both cell lines were analyzed for MGMT promotor status and expression of mismatch repair genes (MMR). The influence of MMR inhibition by cadmium chloride (CdCl2) on the effects of both drugs was evaluated. RESULTS: During the resistance evolution process in vitro, U251/TMZ-R developed MMR deficiency, but MGMT status did not change. U251/TMZ-R cells were more resistant to TMZ than parental U251 cells (cell viability: 92.0% in U251/TMZ-R/69.2% in U251; p = 0.032) yet more sensitive to CCNU (56.4%/80.8%; p = 0.023). The effectiveness of radiotherapy was not reduced in the TMZ-resistant cell line. Combination of CCNU and TMZ showed promising results for both cell lines and overcame resistance. CdCl2-induced MMR deficiency increased cytotoxicity of CCNU. CONCLUSION: Our results confirm MMR deficiency as a crucial process for resistance evolution to TMZ. MMR-deficient TMZ-resistant GBM cells were particularly sensitive to CCNU and to combined CCNU/TMZ. Effectiveness of radiotherapy was preserved in TMZ-resistant cells. Consequently, CCNU might be preferentially considered as a treatment option for recurrent MGMT-methylated GBM and may even be suitable for prevention of resistance evolution in primary treatment.
PURPOSE:Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. While the alkylating agent temozolomide (TMZ) has prolonged overall survival, resistance evolution represents an important clinical problem. Therefore, we studied the effectiveness of radiotherapy and CCNU in an in vitro model of acquired TMZ resistance. METHODS: We studied the MGMT-methylated GBM cell line U251 and its in vitro derived TMZ-resistant subline, U251/TMZ-R. Cytotoxicity of TMZ, CCNU, and radiation was tested. Both cell lines were analyzed for MGMT promotor status and expression of mismatch repair genes (MMR). The influence of MMR inhibition by cadmium chloride (CdCl2) on the effects of both drugs was evaluated. RESULTS: During the resistance evolution process in vitro, U251/TMZ-R developed MMR deficiency, but MGMT status did not change. U251/TMZ-R cells were more resistant to TMZ than parental U251 cells (cell viability: 92.0% in U251/TMZ-R/69.2% in U251; p = 0.032) yet more sensitive to CCNU (56.4%/80.8%; p = 0.023). The effectiveness of radiotherapy was not reduced in the TMZ-resistant cell line. Combination of CCNU and TMZ showed promising results for both cell lines and overcame resistance. CdCl2-induced MMR deficiency increased cytotoxicity of CCNU. CONCLUSION: Our results confirm MMR deficiency as a crucial process for resistance evolution to TMZ. MMR-deficient TMZ-resistant GBM cells were particularly sensitive to CCNU and to combined CCNU/TMZ. Effectiveness of radiotherapy was preserved in TMZ-resistant cells. Consequently, CCNU might be preferentially considered as a treatment option for recurrent MGMT-methylated GBM and may even be suitable for prevention of resistance evolution in primary treatment.
Entities:
Keywords:
Antineoplastic drug resistance; Glioblastoma; Lomustine; Mismatch repair; Temozolomide
Authors: S Fiumicino; S Martinelli; C Colussi; G Aquilina; C Leonetti; M Crescenzi; M Bignami Journal: Int J Cancer Date: 2000-02-15 Impact factor: 7.396
Authors: Denis Faoro; André O von Bueren; Tarek Shalaby; Davide Sciuscio; Marie-Louise Hürlimann; Lucia Arnold; Nicolas U Gerber; Johannes Haybaeck; Michel Mittelbronn; Stefan Rutkowski; Monika Hegi; Michael A Grotzer Journal: J Neurooncol Date: 2010-09-05 Impact factor: 4.130
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent Journal: J Clin Oncol Date: 2013-08-12 Impact factor: 44.544
Authors: Serah Choi; Yao Yu; Matthew R Grimmer; Michael Wahl; Susan M Chang; Joseph F Costello Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Mathew Lozinski; Nikola A Bowden; Moira C Graves; Michael Fay; Paul A Tooney Journal: Cell Oncol (Dordr) Date: 2021-05-31 Impact factor: 6.730
Authors: Wendy Ha; Hatice Sevim-Nalkiran; Ashraf M Zaman; Kazuko Matsuda; Mustafa Khasraw; Anna K Nowak; Liping Chung; Robert C Baxter; Kerrie L McDonald Journal: Sci Rep Date: 2019-02-27 Impact factor: 4.379
Authors: Matthew Gallitto; Rossana Cheng He; Julio F Inocencio; Huaien Wang; Yizhou Zhang; Gintaras Deikus; Isaac Wasserman; Maya Strahl; Melissa Smith; Robert Sebra; Raymund L Yong Journal: J Neurooncol Date: 2020-03-19 Impact factor: 4.130